Appendix A2 has information on the sources for each of the studies' use of: Cohort data, treatment effect, and utilities. Adverse events come from same source as treatment effects.

The exact reference for the source is linked the first time the source appears.

Appendix A2 - Sources for inputs to the models

Study	Comparison	Cohort data sources	Treatment effect sources	Treatment effect source types	Utility sources
Barnett 2018 [1]	Liraglutide vs Sitagliptin	Bailey 2016 [2]	Bailey 2016	Trial	Clarke 2002 [3], Tengs 2000 [4], Bagust 2005 [5]
Basson 2018 [6]	Dulaglutide vs ExenatideQW	Giorgino 2015 [7], WHO 2014 [8]	Giorgino 2015, EliLilly 2014 [9], EMA druglabel [10]	Trial, NMA, Druglabel	Beaudet 2014 [11], Matza 2007 [12], Boye 2011 [13]
Ericsson 2018 [14]	Liraglutide+Basal insulin vs Lixisenatide+Basal insulin, IdegLira	Ahmann 2015 [15], Buse 2014 [16]	Ahmann 2015, inhouse for Liraglutide+Insulin vs Lixisenatide+Insulin, Riddle 2013 [17]	Trial, ITC	Bagust 2005, Kiadaliri 2014 [18], Evans 2013 [19], Ridderstråle 2016 [20]
Tzanetakos 2018 [21]	ExenatideQW vs Insulin Glargine, Liraglutide	Diamant 2010 [22], Scott 2013 [23]	Diamant 2010, Scott 2013	Trial, NMA	Bagust 2005, Matza 2007
Ericsson 2019 [24]	Semaglutide-I vs Dulaglutide, Lixisenatide	Rodbard 2018 [25], Pratley 2018 [26]	Pratley 2018, Witkowski 2018 [27]	Trial, NMA	Kiadaliri 2014, Bagust 2005, Ridderstråle 2016, Evans 2013
Gæde 2019 [28]	Semaglutide-I vs Dulaglutide, ExenatideQW, Liraglutide, Lixisenatide	Ahmann 2018 [29], Pratley 2018	Pratley 2018, Ahmann 2018, Witkowski 2018	Trial, NMA	Beaudet 2014, Lauridsen 2014 [30], Evans 2013
Hunt 2019 [31]	Semaglutide-I vs Insulin Glargine, Dulaglutide	Aroda 2017 [32], Pratley 2018	Aroda 2017, Pratley 2018	Trial	Beaudet 2014, Evans 2013
Johansen 2019 [33]	Semaglutide-I vs Dulaglutide	Pratley 2018	Pratley 2018	Trial	Bagust 2005, CADTH 2017 [34]
Malkin 2019a [35]	Semaglutide-I vs Liraglutide	Ahmann 2018	Ahmann 2018	Trial	Beaudet 2014, Evans 2013
Malkin 2019b [36]	Semaglutide-I vs Dulaglutide	Pratley 2018	Pratley 2018	Trial	Beaudet 2014, Evans 2013
Raya 2019 [37]	IdegLira vs GLP1, Insulin mix+GLP1, Basal insulin, MDI	Price 2018 [38]	Price 2018	RWD	Clarke 2002, Tengs 2000, Palmer 2004 [39], Evans 2013, Bagust 2005
Viljoen 2019 [40]	Semaglutide-I vs Dulaglutide	Pratley 2018	Pratley 2018	Trial	Beaudet 2014, Evans 2013
Bain 2020 [41]	Semaglutide-O vs Empagliflozin, Sitagliptin, Liraglutide	Rodbard 2019 [42], Rosenstock 2019 [43], Pratley 2019 [44]	Rodbard 2019, Rosenstock 2019, Pratley 2019	Trial	Clarke 2002, Bagust 2005, Wasserfallen 2004 [45], Kiberd 1995 [46], Fenwick 2012 [47], Lee 2005 [48], Evans 2013
Capel 2020 [49]	ExenatideQW vs Dulaglutide, Liraglutide, Lixisenatide	Depablos-Valesco 2014 [50], Sicras-Mainar 2014 [51], Mata 2002 [52], National institute of Statistics [53], Alvarez 2008 [54], Gil 2010 [55]	Kayaniyil 2016 [56]	NMA	Depablos-Valesco 2014, Clarke 2004, Bagust 2005, Currie 2006 [57], Lane 2014 [58]
Gorgojo-MartíNez 2020 [59]	Semaglutide-I vs Empagliflozin	Ahrén 2017 [60]	Sharma 2018 [61]	NMA	Beaudet 2014, Evans 2013
Johansen 2020 [62]	Semaglutide-I vs Liraglutide	Sorli 2017 [63]	Sorli 2017	Trial	Beaudet 2014, Evans 2013
MartíN 2020 [64]	Semaglutide-I vs Dulaglutide, Sitagliptin	Pratley 2018, Ahrén 2017	Pratley 2018, Ahrén 2017	Trial	Clarke 2002, Bagust 2005, Wasserfallen 2004, Kiberd 1995, Fenwick 2012, Lee 2005, Evans 2013
Capehorn 2021 [65]	Semaglutide-I vs Empagliflozin	Ahrén 2017, Ahmann 2018, Lingvay 2019 [66], Rodbard 2019	Lingvay 2020 [67]	ITC	Beaudet 2014, Evans 2013
Guzauskas 2021 [68]	Semaglutide-O vs Empagliflozin, Liraglutide, Sitagliptin, MET+SU	NHANES 2019 [69]	Rodbard 2019, Rosenstock 2019, Pratley 2019, Rind 2019 [70]	Trial, NMA	Shao 2019 [71], Sullivan 2016 [72]
Malkin 2021 [73]	Semaglutide-O vs Empagliflozin, Sitagliptin, Liraglutide	Rodbard 2019, Rosenstock 2019, Pratley 2019	Rodbard 2019, Rosenstock 2019, Pratley 2019	Trial	Beaudet 2014, Evans 2013
Risebrough 2021 [74]	Semaglutide-O vs Dulaglutide,Liraglutide,Semaglutide-I	Pratley 2019	Nuhoho 2019 [75]	NMA	Beaudet 2014, Shao 2019, Sullivan 2006 [76]
Ehlers 2022a [77]	Semaglutide-O vs Empagliflozin	Rodbard 2019, Bain 2020 [41], mdcalc 2019	Rodbard 2019, Bain 2020	Trial, CEA	Beaudet 2014, Lauridsen 2014, Foos

Appendix A2 - Sources for inputs to the models

Study	Comparison	Cohort data sources	Treatment effect sources	Treatment effect source types	Utility sources
		[78], Ridderstråle 2018 [79], Folsom 2003 [80], WHO 2002 [81], WHO 2004 [82], Kingry 2007 [83], ADVANCE 2008 [84], Ismail-Beigi 2010 [85]			2018 [86], Turner 2014 [87], NICE CG139 [88]
Ehlers 2022b [89]	Semaglutide-I vs Empagliflozin	Ahrén 2017, Ahmann 2018, Lingvay 2019, Rodbard 2019	Rodbard 2019, Bain 2020, Willis 2017 [90], Fonseca 2011 [91], Capehorn 2021 [65], Ramos 2020b [92]	Trial, CEA, MA, OTHER	Beaudet 2014, Lauridsen 2014, Foos 2018, Turner 2014, NICE CG139
Ekhlasi 2022 [93]	Dulaglutide vs Liraglutide	Lasalvia 2017, Iran survey 2016 [94]	Taheri 2019 [95], Blonde 2015 [96], A study of LY2189265 2016 [97], Dungan 2014 [98], Rosselli 2015 [99], Tarifas iss 2001 [100]	Trial, CEA, OTHER	Liu 2013 [101], Sabapathy 2015 [102], Clarke 2005, Granström 2012 [103]
Eliasson 2022 [104]	Semaglutide-O vs Empagliflozin, Sitagliptin	Rodbard 2019, Rosenstock 2019, Husain 2019 [105]	Rodbard 2019, Rosenstock 2019, Green 2015 [106], Zinman 2015 [107]	Trial	Beaudet 2014, Evans 2013
Franch-Nadal 2022 [108]	Semaglutide-O vs Empagliflozin, Sitagliptin, Liraglutide	Rodbard 2019, Rosenstock 2019, Pratley 2019	Rodbard 2019, Rosenstock 2019, Pratley 2019	Trial	Beaudet 2014, Evans 2013
Hu 2022 [109]	Semaglutide-I vs Dulaglutide	Pratley 2018	Pratley 2018	Trial	Pan 2016 [110], Hou 2019 [111], Clarke 2002
Malkin 2022 [112]	Semaglutide-O vs Empagliflozin, Dulaglutide	Rodbard 2019, Rosenstock 2019	Rodbard 2019, Rosenstock 2019, Nuhoho 2019	Trial, NMA	Beaudet 2014, Evans 2013, Clarke 2002, Bagust 2005, Wasserfallen 2004, Kiberd 1995, Fenwick 2012, Lee 2005
Ruan 2022 [113]	Semaglutide-I vs Dulaglutide	Pratley 2018	Pratley 2018, Marso 2016s [114], Gerstein 2019 [115]	Trial	Pan 2016, Clarke 2002, Johansen 2019 [33], Beaudet 2014, Deng 2015 [116]
Stafford 2022 [117]	Semaglutide-I vs Canagliflozin	Lingvay 2019	Lingvay 2019	Trial	Bagust 2005, CADTH 2017, Fenwick 2012, Hoerger 2010 [118], Evans 2013, Beaudet 2014
Viljoen 2022 [119]	Semaglutide-I vs Dulaglutide	Pratley 2018	Pratley 2021 [120]	ITC	Clarke 2002, Bagust 2005, Wasserfallen 2004, Kiberd 1995, Fenwick 2012, Lee 2005, Evans 2013
Chien 2020 [121]	No main vs classes: MET, SU, DPP4, SGLT2, GLP1, Unspecified insulin	CADTH 2017, UKPDS 1998 [122], Hall 2006 [123], Chen 2013 [124], Friedewald 1972 [125]	CADTH 2017, Downes 2015 [126], Søfteland 2017 [127], Monami 2008 [128], Leiter 2015 [129], Nauck 2011 [130], Ridderstråle 2014 [131], Haring 2013 [132], Matthaei 2015 [133], Wilding 2013 [134]	Review, NMA, Trial, MA	Chen 2018 [135], Currie 2006, Lane 2014
Hu 2021 [136]	No main vs Dapagliflozin + Saxagliptin, Dapagliflozin, Saxagliptin	Mathieu 2015 [137], Matthaei 2015, Rosenstock 2015 [138], Müller-Wieland 2018 [139], Rosenstock 2019	Mathieu 2015, Matthaei 2015, Rosenstock 2015, Müller-Wieland 2018, Rosenstock 2019	Trial	Hou 2019, Pan 2016, Clarke 2002, Cai 2019 [140], Wu 2018a [141], Wu 2018b [142]
Lin 2021 [143]	No main vs Linagliptin 5 mg, Saxagliptin 5 mg, Alogliptin 25 mg, Sitagliptin 100 mg, and Vildagliptin 50 mg	Du 2017 [144]	Craddy 2014 [145]	MTC	Shao 2017 [146], Li 2015 [147], Wang 2015 [148], Gu 2016a [149], Wu 2018a, Wu 2018b, Pan 2016, Li 2021 [150]
Zupa 2021 [151]	Empagliflozin vs Semaglutide-I	Zinman 2015, Marso 2016s	Zinman 2015, Wanner 2016 [152], Marso 2016s	Trial	Rosen 2010 [153], Earnshaw 2011 [154], Itoga 2018 [155], Lehman 2018 [156], Burgers 2014 [157], Mozaffarian 2018 [158], Palmer 2008 [159], Gæde 2019 [28], Neslusan 2018 [160], Zhang 2012 [161], Arias 2017 [162]
Chakravarty 2018 [163]	Dapagliflozin vs Liraglutide, SU, DPP4, Pioglitazone	Barnett 2014 [164]	Barnett 2014	NMA	Vijan 2014 [165], Matza 2007, Timbie

Appendix A2 - Sources for inputs to the models

Study	Comparison	Cohort data sources	Treatment effect sources	Treatment effect source types	Utility sources
					2010 [166], Currie 2006
Neslusan 2018 [160]	Canagliflozin vs Dapagliflozin	Cefalu 2013 [167], Lavalle-González 2013 [168]	Schubert 2017 [169]	NMA	Bagust 2005, Hoerger 2010, Currie 2006, Shingler 2015 [170], Evans 2013, Coyne 2008 [171]
Hou 2019 [111]	Canagliflozin vs Dapagliflozin	Yang 2016 [172], Yang 2010 [173], Xu 2013 [174], Wang 2017 [175]	Zaccardi 2016 [176]	NMA	Pan 2016, Li 2015, Wang 2015, Gu 2016b [177], Shao 2017, Wu 2018b, Wu 2018c
Ramos 2019 [178]	Empagliflozin vs Sitagliptin, Saxagliptin	Zinman 2015	Zinman 2015, Green 2015, Scirica 2013 [179], Wanner 2016, Riddle 2014 [180]	Trial	Beaudet 2014, Bagust 2005
Ramos 2020a [181]	Empagliflozin vs soc & Liraglutide	Zinman 2015, Hayes 2013 [182], Folsom 2003, WHO 2002, WHO 2004	Zinman 2015, Marso 2016L [183]	Trial	Beaudet 2014, Bagust 2005
Ramos 2020b [92]	Empagliflozin vs Semaglutide-O	Rodbard 2019, Bain 2020, Boehringer Ingelheim 2016 [184], Rodbard 2019, Hayes 2013, Folsom 2003, WHO 2002, WHO 2018 [185], ADVANCE 2008 [84], Ismail-Beigi 2010	Rodbard 2019, Patorno 2019, Bain 2020	Trial, RWD, CEA	Beaudet 2014, Foos 2018, Lauridsen 2014
Reifsnider 2020 [186]	Empagliflozin vs Sitagliptin	NHANES 2019	Mearns 2015 [187], Kansal 2019 [188], Balijepalli 2018a [189]	NMA, CEA, ITC	Sullivan 2006, Sullivan 2016, Grandy 2012 [190], Lindgren 2007 [191], Van Hoek 2011 [192], Xu 2011 [193]
Van der linden 2020 [194]	Dapagliflozin vs DPP4	Matthaei 2015, NICE Technology Assessment 418 2016 [195], Hertroijs 2018 [196]	NICE Technology Assessment 418 2016, Matthaei 2015, Schernthaner 2013 [197], Hermansen 2007 [198], Yki-Järvinen 2000 [199], Hollander 2008 [200]	TA, Trial	Sullivan 2016, Kraai 2013 [201], Visser 2016 [202], Redekop 2004 [203], Langelaan 2007 [204], Mazairac 2013 [205], Currie 2006, Van den Hout 2014 [206], Caro 2007 [207]
Ehlers 2021 [208]	Empagliflozin vs Liraglutide	Zinman 2015	Zinman 2014 [209],Zinman 2015, Marso 2016L, Marso 2016S, Balijepalli 2018a	Trial, ITC	Beaudet 2014, Lauridsen 2014, Foos 2018
Gourzoulidis 2021 [210]	Empagliflozin vs Dapagliflozin	Zinman 2015	Zinman 2015, Wiviott 2019 [211]	Trial	Sullivan 2016, Grandy 2012, NICE 2011 [212]
Ramos 2021 [213]	Empagliflozin vs Liraglutide, Sitagliptin	Zinman 2015	Zinman 2015, Balijepalli 2018a, Balijepalli 2018b [214]	Trial, ITC	Li 2018 [215], Beaudet 2014, Bagust 2005
Reifsnider 2021 [216]	Empagliflozin vs Dapagliflozin, Canagliflozin	Zinman 2015	Zinman 2015, Neal 2017 [217], Wiviott 2019	INHOUSE ITC	Grandy 2012, Lindgren 2007, Sullivan 2016, NICE 2011
Lasalvia 2022 [218]	Dapagliflozin vs DPP4	Wiviott 2019	Goring 2014 [219]	NMA	Wiviott 2019, Clarke 2002, Bagust 2005, Brandao 2017 [220], Currie 2006, Barry 1997 [221], Lane 2014
Peng 2022 [222]	SGLT2 vs DPP4	Yang 2022 [223]	Yang 2022	MA	Kuo 2021 [224], Yang 2022
Reifsnider 2022 [225]	Empagliflozin vs Liraglutide	NHANES 2019	Inhouse, Zinman 2015, Kansal 2019, Balijepalli 2018a, FDA victoza 2019 druglabel [226], FDA jardiance 2016 druglabel [227]	NMA, CEA, ITC, Druglabel, Trial	Sullivan 2016, Grandy 2012, Lindgren 2007, Matza 2007, Shao 2019, Boye 2011

ADVANCE: Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation, CADTH: Canadian Agency for Drugs and Technologies in Health, CEA: Cost-effectiveness analysis, EMA: European Medicines Agency, FDA: Food and Drug Administration, ITC: Indirect treatment comparison, MA: Meta-analysis, MTC: Mixed treatment comparison, NMA: Network Meta-analysis, NHANES: National Health and Nutrition Examination Survey, NICE: National Institute for Health and Care Excellence, RWD: Real world data, TA: Technology assessment, WHO: World Health Organisation, MET: Metformin, SU: Sulfonylurea, DPP4: dipeptidylpeptidase-4 inhibitors, GLP1: glucagon-like peptide-1 recepter agonist, SGLT2: sodium-glucose cotransporter-2 inhibitors

References

1. Barnett AH, Arnoldini S, Hunt B, et al. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis. Diabetes, Obesity and Metabolism 2018 Mar; 20 (8): 1921–1927. https://doi.org/10.1111/dom.13318

2. Bailey TS, Takács R, Tinahones FJ, et al. (LIRA-SWITCH) Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. Diabetes, Obesity and Metabolism 2016 Dec; 18 (12): 1191–1198. https://doi.org/10.1111/dom.12736

3. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002; 22 (4): 340–349. https://doi.org/10.1177/0272989X0202200412

4. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000 Jun; 38 (6): 583–637. https://doi.org/10.1097/00005650-200006000-00004

5. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005 Mar; 14 (3): 217–230. https://doi.org/10.1002/hec.910

6. Basson M, Ntais D, Ayyub R, et al. The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France. Diabetes Ther 2018; 9 (1): 13–25. https://doi.org/10.1007/s13300-017-0321-0

7. Giorgino F, Benroubi M, Sun J-H, et al. (AWARD-2) Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride. Diabetes Care 2015 Dec; 38 (12): 2241–2249. https://doi.org/10.2337/dc14-1625

8. WHO. World Health Organization. WHO Report on the Global Tobacco Epidemic [online]. 2014. http://who.int/ tobacco/surveillance/policy/country_profile/frapdf? ua=1.

9. Eli Lilly and Company. Network meta analysis based on publicly available information on type 2 diabetes medications (data analysis on file[from author Basson et al 2018]). 2014

10. EMA. Bydureon: summary of product characteristics. [online]. 2011; . http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Product_Information/ human/002020/WC500108241.pdf. (accessed 2017-01-31) [Accessed 2017 Jan 31]

11. Beaudet A, Clegg J, Thuresson P-O, et al. Review of utility values for economic modeling in type 2 diabetes. Value Health 2014 Jun; 17 (4): 462–470. https://doi.org/10.1016/j.jval.2014.03.003

12. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007 Sep; 16 (7): 1251–1265. https://doi.org/10.1007/s11136-007-9226-0

13. Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2011 Jun; 12 (3): 219–230. https://doi.org/10.1007/s10198-010-0224-8

14. Ericsson Å, Glah D, Lorenzi M, et al. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. PLoS ONE 2018 Jun; 13 (2): e0191953. https://doi.org/10.1371/journal.pone.0191953

15. Ahmann A, Rodbard HW, Rosenstock J, et al. (LIRA-ADD2BASAL) Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2015 Nov; 17 (11): 1056–1064. https://doi.org/10.1111/dom.12539

16. Buse JB, Vilsbøll T, Thurman J, et al. (DUAL-II) Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). Diabetes Care 2014 Oct; 37 (11): 2926–2933. https://doi.org/10.2337/dc14-0785

17. Riddle MC, Aronson R, Home P, et al. (GetGoal-L) Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. Diabetes Care 2013 Sep; 36 (9): 2489–2496. https://doi.org/10.2337/dc12-2454

18. Kiadaliri AA, Gerdtham UG, Eliasson B, et al. Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden. Diabetes Ther 2014 Dec; 5 (2): 591–607. https://doi.org/10.1007/s13300-014-0080-0

19. Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes 2013 Jun; 11: 90. https://doi.org/10.1186/1477-7525-11-90

20. Ridderstråle M, Evans LM, Jensen HH, et al. Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study. Health Qual Life Outcomes 2016 Jan; 14: 13. https://doi.org/10.1186/s12955-016-0411-0

21. Tzanetakos C, Bargiota A, Kourlaba G, et al. Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece. Clin Drug Investig 2018 Jan; 38 (1): 67–77. https://doi.org/10.1007/s40261-017-0586-0

22. Diamant M, Van Gaal L, Stranks S, et al. (DURATION-3) Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet 2010 Jun; 375 (9733): 2234–2243. https://doi.org/10.1016/S0140-6736(10)60406-0

23. Scott DA, Boye KS, Timlin L, et al. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes Metab 2013 Mar; 15 (3): 213–223. https://doi.org/10.1111/dom.12007

24. Ericsson Å, Fridhammar A. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden. Journal of Medical Economics 2019 Oct; 22 (10): 997–1005. https://doi.org/10.1080/13696998.2019.1614009

25. Rodbard HW, Lingvay I, Reed J, et al. (SUSTAIN 5) Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab 2018; : 11. https://doi.org/10.1210/jc.2018-00070

26. Pratley RE, Aroda VR, Lingvay I, et al. (SUSTAIN 7) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology 2018 Apr; 6 (4): 275–286. https://doi.org/10.1016/S2213-8587(18)30024-X

27. Witkowski M, Wilkinson L, Webb N, et al. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs. Diabetes Ther 2018 Jun; 9 (3): 1149–1167. https://doi.org/10.1007/s13300-018-0424-2

28. Gæde P, Johansen P, Tikkanen CK, et al. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. Diabetes Ther 2019 Aug; 10 (4): 1297–1317. https://doi.org/10.1007/s13300-019-0630-6

29. Ahmann AJ, Capehorn M, Charpentier G, et al. (SUSTAIN 3) Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care 2018 Feb; 41 (2): 258–266. https://doi.org/10.2337/dc17-0417

30. Lauridsen JT, Lønborg J, Gundgaard J, et al. Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries. Qual Life Res 2014 Nov; 23 (9): 2645–2650. https://doi.org/10.1007/s11136-014-0712-x

31. Hunt B, Malkin SJP, Moes RGJ, et al. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. BMJ Open Diab Res Care 2019 Oct; 7 (1): e000705. https://doi.org/10.1136/bmjdrc-2019-000705

32. Aroda VR, Bain SC, Cariou B, et al. (SUSTAIN 4) Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The Lancet Diabetes & Endocrinology 2017 May; 5 (5): 355–366. https://doi.org/10.1016/S2213-8587(17)30085-2

33. Johansen P, Håkan-Bloch J, Liu AR, et al. Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. PharmacoEconomics Open 2019 Dec; 3 (4): 537–550. https://doi.org/10.1007/s41669-019-0131-6

34. CADTH. New Drugs for Type 2 Diabetes: Second-Line Therapy – Recommendations Report. Canadian Agency for Drugs and Technologies in Health 2017; : 26

35. Malkin SJP, Russel-Szymczyk M, Liidemann G, et al. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. Diabetes Ther 2019 Feb; 10 (1): 159–176. https://doi.org/10.1007/s13300-018-0542-x

36. Malkin SJP, Russel-Szymczyk M, Psota M, et al. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. Adv Ther 2019 Aug; 36 (8): 2034–2051. https://doi.org/10.1007/s12325-019-00965-y

37. Raya PM, Blasco FJA, Hunt B, et al. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence. Diabetes Obes Metab 2019 Jun; 21 (6): 1349–1356. https://doi.org/10.1111/dom.13660

38. Price H, Blüher M, Prager R, et al. (EXTRA) Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study. Diabetes, Obesity and Metabolism 2018 Apr; 20 (4): 954–962. https://doi.org/10.1111/dom.13182

39. Palmer AJ, Rozea S, Valentinea WJ, et al. Validation of the CORE Diabetes Model Against Epidemiological and Clinical Studies. Current Medical Research and Opinion 2004 Jan; 20 (sup1): S27–S40. https://doi.org/10.1185/030079904X2006

40. Viljoen A, Hoxer CS, Johansen P, et al. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Diabetes Obes Metab 2019 Mar; 21 (3): 611–621. https://doi.org/10.1111/dom.13564

41. Bain SC, Hansen BB, Malkin SJP, et al. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme. Diabetes Ther 2020 Jan; 11 (1): 259–277. https://doi.org/10.1007/s13300-019-00736-6

42. Rodbard HW, Rosenstock J, Canani LH, et al. (PIONEER 2) Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care 2019 Dec; 42 (12): 2272–2281. https://doi.org/10.2337/dc19-0883

43. Rosenstock J, Allison D, Birkenfeld AL, et al. (PIONEER 3) Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea (PIONEER 3). JAMA 2019 Apr; 321 (15): 1466–1480. https://doi.org/10.1001/jama.2019.2942

44. Pratley R, Amod A, Hoff ST, et al. (PIONEER 4) Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet 2019 Jul; 394 (10192): 39–50. https://doi.org/10.1016/S0140-6736(19)31271-1

45. Wasserfallen J-B, Halabi G, Saudan P, et al. Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 2004 Jun; 19 (6): 1594–1599. https://doi.org/10.1093/ndt/gfh175

46. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 1995 Dec; 311 (7020): 1595–1599. https://doi.org/10.1136/bmj.311.7020.1595

47. Fenwick EK, Xie J, Ratcliffe J, et al. The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. Invest Ophthalmol Vis Sci 2012 Feb; 53 (2): 677–684. https://doi.org/10.1167/iovs.11-8992

48. Lee AJ, Morgan CL, Morrissey M, et al. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes. Diabet Med 2005 Nov; 22 (11): 1482–1486. https://doi.org/10.1111/j.1464-5491.2005.01657.x

49. Capel M, Ciudin A, Mareque M, et al. Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus. PharmacoEconomics Open 2020 Jun; 4 (2): 277–286. https://doi.org/10.1007/s41669-019-0171-y

50. Depablos-Velasco P, Salguero-Chaves E, Mata-Poyo J, et al. Quality of life and satisfaction with treatment in subjects with type 2 diabetes: results in Spain of the PANORAMA study. Endocrinol Nutr 2014 Jan; 61 (1): 18–26. https://doi.org/10.1016/j.endonu.2013.05.005

51. Sicras-Mainar A, Navarro-Artieda R, Ibáñez-Nolla J. Clinical and economic characteristics associated with type 2 diabetes. Rev Clin Esp (Barc) 2014 Apr; 214 (3): 121–130. https://doi.org/10.1016/j.rce.2013.11.002

52. Mata M, Antoñanzas F, Tafalla M, et al. [The cost of type 2 diabetes in Spain: the CODE-2 study]. Gac Sanit 2002; 16 (6): 511–520. https://doi.org/10.1016/s0213-9111(02)71973-0

53. National Institute of Statistics, Instituto Nacional de Estadísitica; INE [online]. . http://www.ine.es.

54. Guisasola FÁ, Povedano ST, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes, Obesity and Metabolism 2008; 10 (s1): 25–32. https://doi.org/10.1111/j.1463-1326.2008.00882.x

55. Gil, Montalbán. Prevalence of diabetes mellitus and cardiovascular risk factors in the adult population of the Community of Madrid: PREDIMERC study [in Spanish]. 2010;

56. Kayaniyil S, Lozano-Ortega G, Bennett HA, et al. A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus. Diabetes Ther 2016 Mar; 7 (1): 27–43. https://doi.org/10.1007/s13300-016-0155-1

57. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006 Aug; 22 (8): 1523–1534. https://doi.org/10.1185/030079906X115757

58. Lane S, Levy AR, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin 2014 Jul; 30 (7): 1267–1273. https://doi.org/10.1185/03007995.2014.899207

59. Gorgojo-Martínez JJ, Malkin SJP, Martín V, et al. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. Journal of Medical Economics 2020 Feb; 23 (2): 193–203. https://doi.org/10.1080/13696998.2019.1681436

60. Ahrén B, Masmiquel L, Kumar H, et al. (SUSTAIN 2) Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes: a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol 2017 May; 5 (5): 341–354. https://doi.org/10.1016/S2213-8587(17)30092-X

61. Sharma R, Wilkinson L, Vrazic H, et al. Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis. Current Medical Research and Opinion 2018 Sep; 34 (9): 1595–1603. https://doi.org/10.1080/03007995.2018.1476332

62. Johansen P, Chubb B, Hunt B, et al. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. Adv Ther 2020 May; 37 (5): 2427–2441. https://doi.org/10.1007/s12325-020-01337-7

63. Sorli C, Harashima S, Tsoukas GM, et al. (SUSTAIN 1) Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology 2017 Apr; 5 (4): 251–260. https://doi.org/10.1016/S2213-8587(17)30013-X

64. Martín V, Vidal J, Malkin SJP, et al. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. Adv Ther 2020 Oct; 37 (10): 4427–4445. https://doi.org/10.1007/s12325-020-01464-1

65. Capehorn M, Hallén N, Baker-Knight J, et al. Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting. Diabetes Ther. 2021; 12 (2): 537–555. https://doi.org/10.1007/s13300-020-00989-6

66. Lingvay I, Catarig A-M, Frias JP, et al. (SUSTAIN 8) Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. The Lancet Diabetes & Endocrinology 2019 Nov; 7 (11): 834–844. https://doi.org/10.1016/S2213-8587(19)30311-0

67. Lingvay I, Capehorn MS, Catarig A-M, et al. Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. The Journal of Clinical Endocrinology & Metabolism 2020 Dec; 105 (12): e4593–e4604. https://doi.org/10.1210/clinem/dgaa577

68. Guzauskas GF, Rind DM, Fazioli K, et al. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes. JMCP 2021 Apr; 27 (4): 455–468. https://doi.org/10.18553/jmcp.2021.27.4.455

69. NHANES. Centers for Disease Control and Prevention, National Center for Health Statistics. National Health and Nutrition Examination Survey data. 1999-2008. [online]. 2019; . https://www.cdc.gov/nchs/nhanes/index.htm. (accessed 2019-01-01) [Accessed 2019 Jan 1]

70. Rind. Oral semaglutide for type 2 diabetes: effectiveness and value. Final evidence report [online]. 2019. https://icer.org/wp-content/ uploads/2020/10/ICER_Diabetes_FinalEvidence-Report_120919-1.pdf

71. Shao H, Yang S, Fonseca V, et al. Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation. Pharmacoeconomics 2019 Jul; 37 (7): 921–929. https://doi.org/10.1007/s40273-019-00775-8

72. Sullivan PW, Ghushchyan VH. EQ-5D Scores for Diabetes-Related Comorbidities. Value Health 2016 Dec; 19 (8): 1002–1008. https://doi.org/10.1016/j.jval.2016.05.018

73. Malkin. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials | Elsevier Enhanced Reader. Diabetes Research and Clinical Practice 2021 Mar; . https://doi.org/10.1016/j.diabres.2021.108759

74. Risebrough NA, Baker TM, Zhang L, et al. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics. Clinical Therapeutics 2021 Nov; 43 (11): 1812-1826.e7. https://doi.org/10.1016/j.clinthera.2021.08.015

75. Nuhoho S, Gupta J, Hansen BB, et al. Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis. Diabetes Ther 2019 Dec; 10 (6): 2183–2199. https://doi.org/10.1007/s13300-019-00706-y

76. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006; 26 (4): 410–420. https://doi.org/10.1177/0272989X06290495

77. Ehlers LH, Lamotte M, Ramos MC, et al. The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark. Journal of Comparative Effectiveness Research 2022 Jan; 11 (1): 29–37. https://doi.org/10.2217/cer-2021-0169

78. LDL Calculated [online]. MDCalc. 2019 Jun; . https://www.mdcalc.com/calc/70/ldl-calculated

79. Ridderstråle M, Rosenstock J, Andersen KR, et al. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial. Diabetes Obes Metab 2018 Dec; 20 (12): 2768–2777. https://doi.org/10.1111/dom.13457

80. Folsom AR, Chambless LE, Duncan BB, et al. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 2003 Oct; 26 (10): 2777–2784. https://doi.org/10.2337/diacare.26.10.2777

81. Mackay JL, Eriksen MP. WHO 2002 The tobacco atlas [online]. World Health Organization; 2002. [Accessed 2023 Feb 23]. https://apps.who.int/iris/handle/10665/42580

82. Global status report on alcohol 2004. Geneva: World Health Organization, Dept. of Mental Health and Substance Abuse; 2004

83. Kingry C, Bastien A, Booth G, et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007 Jun; 99 (12A): 68i–79i. https://doi.org/10.1016/j.amjcard.2007.03.025

84. ADVANCE collaborative group et al. (ADVANCE)Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008 Jun; 358 (24): 2560–2572. https://doi.org/10.1056/NEJMoa0802987

85. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010 Aug; 376 (9739): 419–430. https://doi.org/10.1016/S0140-6736(10)60576-4

86. Foos V, McEwan P. Conversion of Hypoglycemia Utility Decrements from Categorical Units Reflecting Event History into Event Specific Disutility Scores Applicable to Diabetes Decision Models. Value in Health 2018 May; 21: S223. https://doi.org/10.1016/j.jval.2018.04.1506

87. Turner KME, Round J, Horner P, et al. An early evaluation of clinical and economic costs and benefits of implementing point of care NAAT tests for Chlamydia trachomatis and Neisseria gonorrhoea in genitourinary medicine clinics in England. Sex Transm Infect 2014 Mar; 90 (2): 104–111. https://doi.org/10.1136/sextrans-2013-051147

88. National Institute for Health and Care Excellence. Overview | Healthcare-associated infections: prevention and control in primary and community care | Guidance | NICE - CG139 [online]. NICE; 2012. [Accessed 2023 Feb 7]. https://www.nice.org.uk/guidance/cg139

89. Ehlers LH, Lamotte M, Ramos MC, et al. The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark. Diabetes Ther 2022 Mar; 13 (3): 489–503. https://doi.org/10.1007/s13300-022-01221-3

90. Willis-a M, Asseburg C, Nilsson A, et al. Multivariate Prediction Equations for HbA1c Lowering, Weight Change, and Hypoglycemic Events Associated with Insulin Rescue Medication in Type 2 Diabetes Mellitus: Informing Economic Modeling. Value Health 2017 Mar; 20 (3): 357–371. https://doi.org/10.1016/j.jval.2016.10.004

91. Fonseca V, Gill J, Zhou R, et al. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011 Sep; 13 (9): 814–822. https://doi.org/10.1111/j.1463-1326.2011.01412.x

92. Ramos M, Cummings MH, Ustyugova A, et al. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK. Diabetes Ther 2020 Sep; 11 (9): 2041–2055. https://doi.org/10.1007/s13300-020-00883-1

93. Ekhlasi M, Taheri S, Yousefi N. Cost-Effectiveness of Dulaglutide Versus Liraglutide for Management of Type 2 Diabetes Mellitus in Iran. Value in Health Regional Issues 2022 Nov; 32: 54–61. https://doi.org/10.1016/j.vhri.2022.07.005

94. WHO. Iran STEPS Noncommunicable Disease Risk Factors Survey 2016 | GHDx [online]. 2016; . https://ghdx.healthdata.org/record/iran-steps-noncommunicable-disease-risk-factors-survey-2016 (accessed 2023-02-24)

95. Taheri S, Saffaei A, Amani B, et al. Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus. Iran J Pharm Res 2019; 18 (4): 2180–2190. https://doi.org/10.22037/ijpr.2019.14733.12619

96. Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 2015 May; 385 (9982): 2057–2066. https://doi.org/10.1016/S0140-6736(15)60936-9

97. Eli Lilly and Company. A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus [online]. clinicaltrials.gov; 2015. [Accessed 2023 Feb 22]. https://clinicaltrials.gov/ct2/show/NCT01558271

98. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014 Oct; 384 (9951): 1349–1357. https://doi.org/10.1016/S0140-6736(14)60976-4

99. Rosselli D, Castaño N, Arciniegas J-A, et al. Costo-efectividad de las estatinas para el tratamiento de dislipidemia en Colombia. Acta Medica Colombiana 2015 Apr; 40 (2): 118–124

100. Manual de tarifas de la entidad promotora de salud del seguro social EPS-ISS. Consejo directivo del instituto de seguros sociales. [online]. 2016. https://lexsaludcolombia.files.wordpress.com/2010/10/tarifas-iss-2001.pdf

101. Liu X, Li C, Gong H, et al. An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study. BMC Public Health 2013 Aug; 13: 729. https://doi.org/10.1186/1471-2458-13-729

102. Sabapathy S, Neslusan C, Yoong K, et al. Impact Of Weight-Related Utilities On The Cost-Effectiveness Of Canagliflozin (Cana) Versus Sitagliptin (Sita) As Third-Line Therapy In Type 2 Diabetes Mellitus (T2dm) In A Canadian Setting. Value in Health 2015 May; 18 (3): A62. https://doi.org/10.1016/j.jval.2015.03.361

103. Granström O, Bergenheim K, McEwan P, et al. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. Prim Care Diabetes 2012 Jul; 6 (2): 127–136. https://doi.org/10.1016/j.pcd.2011.09.003

104. Eliasson B, Ericsson Å, Fridhammar A, et al. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.

PharmacoEconomics Open 2022 May; 6 (3): 343–354. https://doi.org/10.1007/s41669-021-00317-z

105. Husain M, Birkenfeld AL, Donsmark M, et al. (PIONEER 6) Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine 2019 Aug; 381 (9): 841–851. https://doi.org/10.1056/NEJMoa1901118

106. Green JB, Bethel MA, Armstrong PW, et al. (TECOS) Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 2015 Jul; 373 (3): 232–242. https://doi.org/10.1056/NEJMoa1501352

107. Zinman B, Wanner C, Lachin JM, et al. (EMPA-REG OUTCOME - CVD) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015 Nov; 373 (22): 2117–2128. https://doi.org/10.1056/NEJMoa1504720

108. Franch-Nadal J, Malkin SJP, Hunt B, et al. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials. Adv Ther 2022 Jul; 39 (7): 3180–3198. https://doi.org/10.1007/s12325-022-02156-8

109. Hu S, Gu S, Qi C, et al. Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China. Diabetes Obesity Metabolism 2022 Oct; : dom.14881. https://doi.org/10.1111/dom.14881

110. Pan C-W, Sun H-P, Zhou H-J, et al. Valuing Health-Related Quality of Life in Type 2 Diabetes Patients in China. Med Decis Making 2016 Feb; 36 (2): 234–241. https://doi.org/10.1177/0272989X15606903

111. Hou X, Wan X, Wu B. Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China. Front. Pharmacol. 2019 May; 10: 480. https://doi.org/10.3389/fphar.2019.00480

112. Malkin SJP, Carvalho D, Costa C, et al. ´The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. Diabetol Metab Syndr 2022 Dec; 14 (1): 32. https://doi.org/10.1186/s13098-022-00801-4

113. Ruan Z, Ung COL, Shen Y, et al. Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China. Diabetes Ther 2022 Oct; 13 (10): 1737–1753. https://doi.org/10.1007/s13300-022-01301-4

114. Marso-S SP, Bain SC, Consoli A, et al. (SUSTAIN 6) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. https://doi-org.zorac.aub.aau.dk/10.1056/NEJMoa1607141 [online] 2016; . https://doi.org/10.1056/NEJMoa1607141 [Accessed 2021 Feb 15]

115. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019 Jul; 394 (10193): 121–130. https://doi.org/10.1016/S0140-6736(19)31149-3

116. Deng J, Gu S, Shao H, et al. Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies. J Med Econ 2015; 18 (11): 974–989. https://doi.org/10.3111/13696998.2015.1067622

117. Stafford S, Bech PG, Fridhammar A, et al. Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting. Appl Health Econ Health Policy 2022 Jul; 20 (4): 543–555. https://doi.org/10.1007/s40258-022-00726-z

118. Hoerger TJ, Wittenborn JS, Segel JE, et al. A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences. Am J Kidney Dis 2010 Mar; 55 (3): 452–462. https://doi.org/10.1053/j.ajkd.2009.11.016

119. Viljoen A, Chubb B, Malkin SJP, et al. The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK. Eur J Health Econ 2022 Sep; . https://doi.org/10.1007/s10198-022-01514-1

120. Pratley RE, Catarig A-M, Lingvay I, et al. An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Diabetes Obes Metab 2021 Nov; 23 (11): 2513–2520. https://doi.org/10.1111/dom.14497

121. Chien C-L, Chen Y-C, Malone DC, et al. Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. Current Medical Research and Opinion 2020 Oct; 36 (10): 1619–1626. https://doi.org/10.1080/03007995.2020.1815686

122. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998 Sep; 352 (9131): 837–853. https://doi.org/10.1016/S0140-6736(98)07019-6

123. Hall DMB, Cole TJ. What use is the BMI? Arch Dis Child 2006 Apr; 91 (4): 283–286. https://doi.org/10.1136/adc.2005.077339

124. Chen. The relationships of diabetes medication on the risk of acute myocardial infarction, stroke, heart failure, and death in patients with type 2 diabetes – participants in National Diabetes Care Management Program [master's thesis]. Taipei: Taipei Medical University; 2013

125. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 Jun; 18 (6): 499–502

126. Downes MJ, Bettington EK, Gunton JE, et al. Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. PeerJ 2015; 3: e1461. https://doi.org/10.7717/peerj.1461

127. Søfteland E, Meier JJ, Vangen B, et al. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. Diabetes Care 2017 Feb; 40 (2): 201–209. https://doi.org/10.2337/dc16-1347

128. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008 Aug; 81 (2): 184–189. https://doi.org/10.1016/j.diabres.2008.04.007

129. Leiter LA, Yoon K-H, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015 Mar; 38 (3): 355–364. https://doi.org/10.2337/dc13-2762

130. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011 Sep; 34 (9): 2015–2022. https://doi.org/10.2337/dc11-0606

131. Ridderstråle M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014 Sep; 2 (9): 691–700. https://doi.org/10.1016/S2213-8587(14)70120-2

132. Häring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013 Nov; 36 (11): 3396–3404. https://doi.org/10.2337/dc12-2673

133. Matthaei S, Bowering K, Rohwedder K, et al. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 2015 Mar; 38 (3): 365–372. https://doi.org/10.2337/dc14-0666

134. Wilding JPH, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013 Dec; 67 (12): 1267–1282. https://doi.org/10.1111/ijcp.12322

135. Chen. Health utilities in patients with diabetes in Taiwan [master's thesis]. Taipei: Taipei Medical University; 2018

136. Hu S, Deng X, Ma Y, et al. Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus. Appl Health Econ Health Policy 2021 Jan; 19 (1): 69–79. https://doi.org/10.1007/s40258-020-00603-7

137. Mathieu C, Ranetti AE, Li D, et al. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. Diabetes Care 2015 Nov; 38 (11): 2009–2017. https://doi.org/10.2337/dc15-0779

138. Rosenstock J, Hansen L, Zee P, et al. Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin. Diabetes Care 2015 Mar; 38 (3): 376–383. https://doi.org/10.2337/dc14-1142

139. Müller-Wieland D, Kellerer M, Cypryk K, et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab 2018 Nov; 20 (11): 2598–2607. https://doi.org/10.1111/dom.13437

140. Cai X, Shi L, Yang W, et al. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. J Med Econ 2019 Apr; 22 (4): 336–343. https://doi.org/10.1080/13696998.2019.1570220

141. Wu B, Ma J, Zhang S, et al. (COMT, Wu 2018a) Development and validation of a Health Policy Model of Type 2 diabetes in Chinese setting. Journal of Comparative Effectiveness Research 2018 Aug; 7 (8): 749–763. https://doi.org/10.2217/cer-2018-0001

142. Wu B, Wan X, Ma J. wu 2018b Cost-effectiveness of prevention and management of diabetic foot ulcer and amputation in a health resource-limited setting. J Diabetes 2018 Apr; 10 (4): 320–327. https://doi.org/10.1111/1753-0407.12612

143. Lin W-Q, Cai Z, Chen T, et al. Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China. Front. Endocrinol. 2021 Aug; 12: 684960. https://doi.org/10.3389/fendo.2021.684960

144. Du J, Liang L, Fang H, et al. Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study): DU et al. Diabetes Obes Metab 2017 Nov; 19 (11): 1513–1520. https://doi.org/10.1111/dom.12942

145. Craddy P, Palin H-J, Johnson KI. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. Diabetes Ther 2014 Jun; 5 (1): 1–41. https://doi.org/10.1007/s13300-014-0061-3

146. Shao H, Zhai S, Zou D, et al. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Current Medical Research and Opinion 2017 Feb; 33 (2): 359–369. https://doi.org/10.1080/03007995.2016.1257978

147. Li T, Liu M, Ben H, et al. Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. Clin Drug Investig 2015 Jun; 35 (6): 365–374. https://doi.org/10.1007/s40261-015-0290-x

148. Wang H, Lin X, Zhang Z, et al. The Economic Burden of Inpatients With Type 2 Diabetes: A Case Study in a Chinese Hospital. Asia Pac J Public Health 2015 Mar; 27 (2_suppl): 49S-54S. https://doi.org/10.1177/1010539515572220

149. Gu-A S, Zeng Y, Yu D, et al. Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China. PLoS ONE 2016; 11 (11): e0167190. https://doi.org/10.1371/journal.pone.0167190

150. Li C, Zhou H, Wang P. Health utility of type 2 diabetes patients using basal insulin in China: results from the BEYOND II study. Acta Diabetol 2021 Mar; 58 (3): 329–339. https://doi.org/10.1007/s00592-020-01618-1

151. Zupa MF, Codario RA, Smith KJ. Cost–effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes. Journal of Comparative Effectiveness Research 2021 Oct; 10 (15): 1133–1141. https://doi.org/10.2217/cer-2021-0016

152. Wanner C, Inzucchi SE, Lachin JM, et al. (EMPA-REG OUTCOME - KIDNEY/RENAL) Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine 2016 Jul; 375 (4): 323–334. https://doi.org/10.1056/NEJMoa1515920

153. Rosen VM, Taylor DCA, Parekh H, et al. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US. Pharmacoeconomics 2010; 28 (1): 47–60. https://doi.org/10.2165/11531440-000000000-00000

154. Earnshaw SR, Scheiman J, Fendrick AM, et al. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011 Feb; 171 (3): 218–225. https://doi.org/10.1001/archinternmed.2010.525

155. Itoga NK, Minami HR, Chelvakumar M, et al. Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test. Vasc Med 2018 Apr; 23 (2): 97–106. https://doi.org/10.1177/1358863X17745371

156. Lehman EP, Cowper PA, Randolph TC, et al. Usefulness and Cost-Effectiveness of Universal Echocardiographic Contrast to Detect Left Ventricular Thrombus in Patients with Heart Failure and Reduced Ejection Fraction. Am J Cardiol 2018 Jul; 122 (1): 121–128. https://doi.org/10.1016/j.amjcard.2018.03.016

157. Burgers LT, Nauta ST, Deckers JW, et al. Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment? Int J Cardiol 2014 Oct; 176 (3): 980–987. https://doi.org/10.1016/j.ijcard.2014.08.134

158. Mozaffarian D, Liu J, Sy S, et al. Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study. PLoS Med 2018 Oct; 15 (10): e1002661. https://doi.org/10.1371/journal.pmed.1002661

159. Palmer AJ, Valentine WJ, Chen R, et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 2008 Apr; 23 (4): 1216–1223. https://doi.org/10.1093/ndt/gfn082

160. Neslusan C, Teschemaker A, Willis M, et al. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes Ther 2018 Feb; 9 (2): 565–581. https://doi.org/10.1007/s13300-018-0371-y

161. Zhang P, Brown MB, Bilik D, et al. Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from Translating Research Into Action for Diabetes (TRIAD). Diabetes Care 2012 Nov; 35 (11): 2250–2256. https://doi.org/10.2337/dc11-2478

162. Arias. United States Life Tables, 2017. National Vital Statistics Report. Centers for Disease Control and Prevention, GA, USA (2017). 2017;

163. Chakravarty A, Rastogi M, Dhankhar P, et al. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting. Journal of Medical Economics 2018 May; 21 (5): 497–509. https://doi.org/10.1080/13696998.2018.1434182

164. Barnett A, Orme M. Systematic Review and Network Meta-analysis to Compare Dapagliflozin with other Diabetes Medications in Combination with Metformin for Adults with Type 2 Diabetes. Intern Med [online] 2014; 01 (s6). https://doi.org/10.4172/2165-8048.S6-006 [Accessed 2023 Feb 24]

165. Vijan S, Sussman JB, Yudkin JS, et al. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 2014 Aug; 174 (8): 1227–1234. https://doi.org/10.1001/jamainternmed.2014.2894

166. Timbie JW, Hayward RA, Vijan S. Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med 2010 Jun; 170 (12): 1037–1044. https://doi.org/10.1001/archinternmed.2010.150

167. Cefalu WT, Leiter LA, Yoon K-H, et al. (CANTATA-SU) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. The Lancet 2013 Sep; 382 (9896): 941–950. https://doi.org/10.1016/S0140-6736(13)60683-2

168. Lavalle-González FJ, Januszewicz A, Davidson J, et al. (CANA-UNNAMED) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56 (12): 2582–2592. https://doi.org/10.1007/s00125-013-3039-1

169. Schubert A, Buchholt AT, El Khoury AC, et al. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. Curr Med Res Opin 2017 Jun; 33 (6): 1155–1163. https://doi.org/10.1080/03007995.2017.1310091

170. Shingler S, Fordham B, Evans M, et al. Utilities for treatment-related adverse events in type 2 diabetes. J Med Econ 2015 Jan; 18 (1): 45–55. https://doi.org/10.3111/13696998.2014.971158

171. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008 Jun; 101 (11): 1388–1395. https://doi.org/10.1111/j.1464-410X.2008.07601.x

172. Yang W, Han P, Min K-W, et al. (brugt i Hou2019) Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial. Journal of Diabetes 2016; 8 (6): 796–808. https://doi.org/10.1111/1753-0407.12357

173. Yang W, Lu J, Weng J, et al. Prevalence of Diabetes among Men and Women in China. N Engl J Med 2010 Mar; 362 (12): 1090–1101. https://doi.org/10.1056/NEJMoa0908292

174. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013 Sep; 310 (9): 948–959. https://doi.org/10.1001/jama.2013.168118

175. Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013. JAMA 2017 Jun; 317 (24): 2515. https://doi.org/10.1001/jama.2017.7596

176. Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016 Aug; 18 (8): 783–794. https://doi.org/10.1111/dom.12670

177. Gu-B S, Mu Y, Zhai S, et al. Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China. PLoS ONE 2016; 11 (11): e0165629. https://doi.org/10.1371/journal.pone.0165629

178. Ramos M, Foos V, Ustyugova A, et al. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease. Diabetes Ther 2019 Dec; 10 (6): 2153–2167. https://doi.org/10.1007/s13300-019-00701-3

179. Scirica BM, Bhatt DL, Braunwald E, et al. (SAVOR-TIMI 53) Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine 2013 Oct; 369 (14): 1317–1326. https://doi.org/10.1056/NEJMoa1307684

180. Riddle MC, Bolli GB, Ziemen M, et al. (EDITION 1) New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial. Diabetes Care 2014 Oct; 37 (10): 2755–2762. https://doi.org/10.2337/dc14-0991

181. Ramos M, Ustyugova A, Hau N, et al. Cost–effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes. Journal of Comparative Effectiveness Research 2020 Jun; : cer-2020-0071. https://doi.org/10.2217/cer-2020-0071

182. Hayes AJ, Leal J, Gray AM, et al. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013 Sep; 56 (9): 1925–1933. https://doi.org/10.1007/s00125-013-2940-y

183. Marso-L SP, Daniels GH, Brown-Frandsen K, et al. (LEADER) Marso-L Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016 Jul; 375 (4): 311–322. https://doi.org/10.1056/NEJMoa1603827

184. Boehringer Ingelheim. (EMPA-REG OUTCOME H2H-SU) A Phase III Randomised, Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 10773 Compared to Glimepiride Administered Orally During 104 Weeks With a 104 Week Extension Period in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Metformin Treatment [online]. clinicaltrials.gov; 2016. [Accessed 2023 Feb 5]. https://clinicaltrials.gov/ct2/show/NCT01167881

185. WHO. Global status report on alcohol and health [online]. 2018; . https://www.who.int/publications-detail-redirect/9789241565639 (accessed 2023-02-23)

186. Reifsnider O, Kansal A, Pimple P, et al. Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States. Diabetes Obes Metab 2020; 23 (3): 791–799. https://doi.org/10.1111/dom.14268

187. Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One 2015; 10 (4): e0125879. https://doi.org/10.1371/journal.pone.0125879

188. Kansal A, Reifsnider OS, Proskorovsky I, et al. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial. Diabet Med 2019 Nov; 36 (11): 1494–1502. https://doi.org/10.1111/dme.14076

189. Balijepalli-A C, Shirali R, Kandaswamy P, et al. Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons. Diabetes Ther 2018 Aug; 9 (4): 1491–1500. https://doi.org/10.1007/s13300-018-0456-7

190. Grandy S, Fox KM, SHIELD Study Group. Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study. Health Qual Life Outcomes 2012 Aug; 10: 99. https://doi.org/10.1186/1477-7525-10-99

191. Lindgren P, Graff J, Olsson AG, et al. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J 2007 Jun; 28 (12): 1448–1453. https://doi.org/10.1093/eurheartj/ehm020

192. van Hoek AJ, Underwood A, Jit M, et al. The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. PLoS One 2011 Mar; 6 (3): e17030. https://doi.org/10.1371/journal.pone.0017030

193. Xu R, Insinga RP, Golden W, et al. EuroQol (EQ-5D) health utility scores for patients with migraine. Qual Life Res 2011 May; 20 (4): 601–608. https://doi.org/10.1007/s11136-010-9783-5

194. Van der Linden N, Van Olst S, Nekeman S, et al. The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands. Diabet Med 2020 Apr; 38 (4). https://doi.org/10.1111/dme.14371

195. NICE. Dapagliflozin in triple therapy for treating type 2 diabetes [online]. 2016. [Accessed 2020 May 1]. https://www.nice.org.uk/guidance/ta418/resources/ dapagliflozin-in-triple-therapy-for-treating-type-2-diabetespdf-82604609944261 (accessed 2020-05-01) [Accessed 2020 May 1]

196. Hertroijs DFL, Elissen AMJ, Brouwers MCGJ, et al. A risk score including body mass index, glycated haemoglobin and triglycerides predicts future glycaemic control in people with type 2 diabetes. Diabetes Obes Metab 2018 Mar; 20 (3): 681–688. https://doi.org/10.1111/dom.13148

197. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013 Sep; 36 (9): 2508–2515. https://doi.org/10.2337/dc12-2491

198. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007 Sep; 9 (5): 733–745. https://doi.org/10.1111/j.1463-1326.2007.00744.x

199. Yki-Järvinen H, Dressler A, Ziemen M, et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000 Aug; 23 (8): 1130–1136. https://doi.org/10.2337/diacare.23.8.1130

200. Hollander P, Cooper J, Bregnhøj J, et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008 Nov; 30 (11): 1976–1987. https://doi.org/10.1016/j.clinthera.2008.11.001

201. Kraai IH, Vermeulen KM, Luttik MLA, et al. Preferences of heart failure patients in daily clinical practice: quality of life or longevity? Eur J Heart Fail 2013 Oct; 15 (10): 1113–1121. https://doi.org/10.1093/eurjhf/hft071

202. Visser J. Artsen zuinig met nieuwe diabetesmiddelen. 2016; [Accessed 2020 May 1]

203. Redekop WK, Stolk EA, Kok E, et al. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab 2004 Dec; 30 (6): 549–556. https://doi.org/10.1016/s1262-3636(07)70154-4

204. Langelaan M, de Boer MR, van Nispen RMA, et al. Impact of visual impairment on quality of life: a comparison with quality of life in the general population and with other chronic conditions. Ophthalmic Epidemiol 2007; 14 (3): 119–126. https://doi.org/10.1080/09286580601139212

205. Mazairac AHA, Blankestijn PJ, Grooteman MPC, et al. The cost-utility of haemodiafiltration versus haemodialysis in the Convective Transport Study. Nephrol Dial Transplant 2013 Jul; 28 (7): 1865–1873. https://doi.org/10.1093/ndt/gft045

206. van den Hout WB, Caljouw MAA, Putter H, et al. Cost-effectiveness of cranberry capsules to prevent urinary tract infection in long-term care facilities: economic evaluation with a randomized controlled trial. J Am Geriatr Soc 2014 Jan; 62 (1): 111–116. https://doi.org/10.1111/jgs.12595

207. Jaime Caro J, Ozer Stillman I, Danel A, et al. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. Journal of Medical Economics 2007 Jan; 10 (3): 239–254. https://doi.org/10.3111/13696990701438629

208. Ehlers LH, Lamotte M, Monteiro S, et al. The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease. Diabetes Ther 2021 May; 12 (5): 1523–1534. https://doi.org/10.1007/s13300-021-01040-y

209. Zinman B, Inzucchi SE, Lachin JM, et al. (EMPA-REG OUTCOME - DESIGN) Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of

empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol 2014 Jun; 13: 102. https://doi.org/10.1186/1475-2840-13-102

210. Gourzoulidis G, Tzanetakos C, Ioannidis I, et al. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece. Clin Drug Investig 2021 Apr; 41 (4): 371–380. https://doi.org/10.1007/s40261-021-01013-w

211. Wiviott SD, Raz I, Bonaca MP, et al. (DECLARE-TIMI 58) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes DECLARE. N Engl J Med 2019 Jan; 380 (4): 347–357. https://doi.org/10.1056/NEJMoa1812389

212. NICE. Type 2 diabetes: The management of type 2 diabetes [online]. 2011; . https://www.nice.org.uk/guidance/CG87 (accessed 2011-01-01) [Accessed 2011 Jan 1]

213. Ramos M, Men P, Wang X, et al. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. Cost Eff Resour Alloc 2021 Dec; 19 (1): 46. https://doi.org/10.1186/s12962-021-00299-z

214. Balijepalli-B C, Ayers D, Kandaswamy P, et al. PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS. Value in Health 2018 Oct; 21: S120–S121. https://doi.org/10.1016/j.jval.2018.09.718

215. Li T, Wan X, Ma J, et al. Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes. Adv Ther 2018 Dec; 35 (12): 2214–2223. https://doi.org/10.1007/s12325-018-0823-9

216. Reifsnider OS, Kansal AR, Gandhi PK, et al. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Res Care 2021 Apr; 9 (1): e001313. https://doi.org/10.1136/bmjdrc-2020-001313

217. Neal B, Perkovic V, Mahaffey KW, et al. (CANVAS) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017 Aug; 377 (7): 644–657. https://doi.org/10.1056/NEJMoa1611925

218. Lasalvia P, Gil-Rojas Y, García Á. Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia. Expert Review of Pharmacoeconomics & Outcomes Research 2022 Aug; 22 (6): 955–964. https://doi.org/10.1080/14737167.2022.2044310

219. Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 2014 May; 16 (5): 433–442. https://doi.org/10.1111/dom.12239

220. Brandão SMG, Hueb W, Ju YT, et al. Utility and quality-adjusted life-years in coronary artery disease: Five-year follow-up of the MASS II trial. Medicine (Baltimore) 2017 Dec; 96 (50): e9113. https://doi.org/10.1097/MD.0000000000009113

221. Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract 1997 Jan; 44 (1): 49–60

222. Peng Z, Yang C, Ou H, et al. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: A model-based simulation analysis using 10-year real-world data and targeted literature review. Diabetes Obesity Metabolism 2022 Jul; 24 (7): 1328–1337. https://doi.org/10.1111/dom.14708

223. Yang C-T, Peng Z-Y, Chen Y-C, et al. Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review. Front Endocrinol (Lausanne) 2022; 13: 836365. https://doi.org/10.3389/fendo.2022.836365

224. Kuo S, Yang C-T, Chen H-Y, et al. Valuing health states of people with type 2 diabetes: Analyses of the nationwide representative linked databases. J Diabetes Investig 2021 Sep; 12 (9): 1749–1758. https://doi.org/10.1111/jdi.13520

225. Reifsnider OS, Pimple P, Brand S, et al. Cost-effectiveness empagliflozin versus liraglutide for type 2 diabetes in the United States. Diabetes Obesity Metabolism 2022 Apr; 24 (4): 652–661. https://doi.org/10.1111/dom.14625

226. US Food and Drug Administration. VICTOZA® (liraglutide) injection, for subcutaneous use: Prescribing Information. Initial U.S. Approval: 2010. [online]. 2019. [Accessed 2020 Jan 17]. https://www.accessdata.fda.gov/drugsatfda_docs/label/201 9/022341s031lbl.pdf

227. US Food and Drug Administration. JARDIANCE® (empagliflozin) tablets, for oral use: Prescribing Information. Initial U.S. Approval: 2014. [online]. 2016. [Accessed 2020 Jan 17]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/ 204629s008lbl.pdf